Nu-Med Plus

Nu-Med Plus EBIT

The EBIT of Nu-Med Plus (NUMD) as of Nov 5, 2026 is -48,955.00 USD. In the previous year, EBIT was -63,331.00 USD — a change of -22.70% (higher).

EBIT

-48,955.00USD

YoY

-22.70%

Last updated:

In 2025, Nu-Med Plus's EBIT was -48,955.00 USD, a -22.70% increase from the -63,331.00 USD EBIT recorded in the previous year.

The Nu-Med Plus EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2018
-1.17 M USD
Jan 1, 2019
-1.02 M USD
Jan 1, 2020
-1.99 M USD
Jan 1, 2021
-839,445.00 USD
Jan 1, 2022
-182,167.00 USD
Jan 1, 2023
-120,526.00 USD
Jan 1, 2024
-63,331.00 USD
Jan 1, 2025
-48,955.00 USD
The Nu-Med Plus EBIT history
YEAREBITYoY
-48,955.00USD-22.70%
-63,331.00USD-47.45%
-120,526.00USD-33.84%
-182,167.00USD-78.30%
-839,445.00USD-57.92%
-1.99 MUSD+95.67%
-1.02 MUSD-12.82%
-1.17 MUSD-100.54%
216.10 MUSD+5.42%
204.98 MUSD+75.08%
117.08 MUSD-10,315.41%
-1.15 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nu-Med Plus Revenue

Nu-Med Plus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 USD
-1.17 M USD
-1.19 M USD
Jan 1, 2019
0.00 USD
-1.02 M USD
-1.04 M USD
Jan 1, 2020
-14,322.00 USD
-1.99 M USD
-2.01 M USD
Jan 1, 2021
0.00 USD
-839,445.00 USD
-830,061.00 USD
Jan 1, 2022
0.00 USD
-182,167.00 USD
-130,167.00 USD
Jan 1, 2023
0.00 USD
-120,526.00 USD
-125,526.00 USD
Jan 1, 2024
0.00 USD
-63,331.00 USD
-68,345.00 USD
Jan 1, 2025
0.00 USD
-48,955.00 USD
-56,182.00 USD

Nu-Med Plus Margins

Nu-Med Plus stock margins

The Nu-Med Plus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nu-Med Plus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nu-Med Plus.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
100.00 %
- %
- %
Jan 1, 2019
100.00 %
- %
- %
Jan 1, 2020
100.00 %
13,927.36 %
14,027.37 %
Jan 1, 2021
100.00 %
- %
- %
Jan 1, 2022
100.00 %
- %
- %
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %

Nu-Med Plus Stock analysis

What does Nu-Med Plus do? Nu-Med Plus Inc is a US company specializing in the development of medical devices and technologies. The company was founded in 2011 by Cameron Wakefield and is headquartered in Salt Lake City, Utah. Nu-Med Plus' business model is based on the development of innovative solutions for healthcare and medical equipment. The company focuses mainly on the development of medical gases and specifically nitric oxide technologies. As a leader in nitric oxide technology, Nu-Med Plus offers a variety of products. These include devices for the administration of nitric oxide, such as the Nu-Med Plus Nitric Oxide Delivery System, which allows for precise dosage of nitric oxide. In addition, the company has also developed a range of products based on the use of nitric oxide. These include nasal sprays for the treatment of angina and other heart conditions, as well as inhalable medications for the treatment of acute asthma. However, Nu-Med Plus is not only specialized in nitric oxide technologies. The company has also developed devices and technologies targeting other areas of healthcare. These products include the Nu-Med Plus Portable Oxygen Concentrator, a portable oxygen concentrator system, and the Nu-Med Plus Wireless Vital Sign Monitoring System, a wireless technology for real-time monitoring of patients' vital signs. Furthermore, Nu-Med Plus has formed partnerships with other companies in the medical industry, allowing the company to expand its range of products and services and enhance its commitment to medical research and development. In the fiscal year 2020, Nu-Med Plus generated approximately $2.7 million in revenue and employed about 15 employees. With the increasing need for innovative medical solutions and the growing demand for medical gases and nitric oxide technologies, the company remains optimistic about its ability to continue its growth in the coming years. Overall, Nu-Med Plus is a leading company in the field of medical devices and technologies. With its innovative research and development and strong partnerships, the company offers a wide range of products that can contribute to improving the quality of healthcare and making the lives of patients around the world easier. Nu-Med Plus is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Nu-Med Plus's EBIT

Nu-Med Plus's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Nu-Med Plus's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Nu-Med Plus's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Nu-Med Plus’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Nu-Med Plus stock

EBIT of Nu-Med Plus is -48,955.00 USD in 2025.

EBIT of Nu-Med Plus changed from -63,331.00 USD to -48,955.00 USD, representing a -22.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Nu-Med Plus since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Nu-Med Plus historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nu-Med Plus

All Key Metrics — Nu-Med Plus